Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5

FDA recall notice · announced February 1, 2023 · Glaxosmithkline Consumer Healthcare Holdings Dba Haleon

Class I FDA/FSIS Class I: reasonable probability that use will cause serious adverse health consequences or death.

The product

Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5

Reason for recall

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Notes

Distribution: Nationwide in the USA.
Lot/code information: Lot: R93517, R94072, R94073, Exp 02/29/2024; T00655, Exp 03/31/2025
Quantity: 209,292 capsules
Status: Terminated
Products in this recall event:
- Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3 (D-0182-2023)
- Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940 (D-0181-2023)
- Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5 (D-0183-2023)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.